Patient-level data showed month 3 vision outcomes did not predict long-term neovascular age-related macular degeneration outcomes when treated with ranibizumab, according to presentation at the virtual American Society of Retina Specialists meeting.
“In this analysis, we explored the HARBOR data to address the key question: Do month 3 vision outcomes in patients with neovascuar AMD predict long-term outcomes? Particularly as novel mechanism therapeutics are being developed for neovascular AMD, the answer to this question may inform optimal timing for switching to novel treatments,”
Uncategorized